ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
Rhea-AI Summary
Telix (ASX: TLX, NASDAQ: TLX) announced that safety and tolerability data from Part 1 of the ProstACT Global Phase 3 study will be presented as a late-breaking oral presentation at ASCO 2026 on June 1, 2026.
Part 1 is a safety and dosimetry lead-in evaluating TLX591-Tx (177Lu-rosopatamab tetraxetan) plus standard of care in PSMA-positive mCRPC; abstract LBA5009, presenting author Pedro C. Barata, MD.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – TLX
On the day this news was published, TLX gained 1.17%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TLX was roughly flat at -0.09% while several biotech peers like RARE (-4.25%), LGND (-2.09%), MLTX (-3.58%) and ZLAB (-3.21%) declined, suggesting this ASCO late-breaking abstract is a company-specific driver rather than a sector-wide move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | Phase 3 GBM dosing | Positive | -0.4% | First patient dosed in Phase 3 IPAX BrIGHT glioblastoma trial. |
| Mar 09 | ProstACT Part 1 success | Positive | +5.5% | ProstACT Global Part 1 met primary safety and dosimetry objectives. |
| Jan 16 | BiPASS US patient dosed | Positive | +4.4% | First U.S. patient dosed in Phase 3 BiPASS prostate diagnosis study. |
| Dec 21 | Precision portfolio update | Positive | +3.2% | Positive Phase 3 Illuccix China data and CDx regulatory updates. |
| Sep 09 | BiPASS trial initiated | Positive | +4.3% | Phase 3 BiPASS PSMA-PET imaging trial initiation in prostate cancer. |
Clinical trial updates have generally seen positive price alignment, with one recent divergence.
Over the past months, Telix has repeatedly advanced its clinical portfolio. Key events include ProstACT Global Part 1 meeting primary objectives on Mar 9, 2026 and multiple Phase 3 initiations and updates across prostate cancer and glioblastoma. Same-tag clinical trial news has often coincided with positive moves, such as BiPASS and Illuccix updates, suggesting the ProstACT ASCO 2026 late-breaking selection fits an ongoing pattern of portfolio maturation.
Historical Comparison
In the past year, TLX released 5 clinical trial updates averaging a 3.41% move. Today’s near-flat -0.09% reaction to the ProstACT ASCO late-breaker is modest versus prior responses.
Clinical news shows progression from initial Phase 3 starts (BiPASS, IPAX BrIGHT) through ProstACT Global Part 1 achieving primary objectives to now being featured as a late-breaking ASCO 2026 oral presentation.
Market Pulse Summary
This announcement highlights that ProstACT Global Phase 3 (Part 1) safety and tolerability data earned a late-breaking oral slot at ASCO 2026, underscoring potential clinical relevance for PSMA-targeted TLX591-Tx in mCRPC. In context, Telix previously reported that Part 1 met its primary objectives and advanced into Part 2. Investors may watch for detailed safety, dosimetry and real-world design aspects when the abstract is released on June 1, 2026.
Key Terms
phase 3 medical
radio antibody-drug conjugate medical
standard of care medical
dosimetry medical
biodistribution medical
metastatic castration-resistant prostate cancer medical
psma medical
radioligand medical
AI-generated analysis. Not financial advice.
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the ProstACT Global Phase 3 study (Part 1) will be presented as a late-breaking oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL.
ProstACT Global is an international, multi-center, Phase 3 trial evaluating Telix’s lead prostate-specific membrane antigen (PSMA) targeted lutetium radio antibody-drug conjugate (rADC) therapy, TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan), in combination with standard of care (SoC) versus SoC alone. The study is designed to reflect real-world global clinical practice with the aim to support broad geographic adoption in the evolving prostate cancer treatment landscape.
Part 1 of the trial is a safety and dosimetry lead-in, assessing the tolerability, biodistribution, and radiation dose profile of TLX591-Tx when administered in combination with SoC in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
The selection of this abstract as a late-breaking oral presentation at ASCO underscores the potential clinical significance of the ProstACT Global study and Telix’s continued leadership in advancing next-generation radiopharmaceutical therapies for prostate cancer.
Presentation details are as follows:
Presenting Author: Pedro C. Barata, MD, MSc, University Hospitals Seidman Cancer Center, Cleveland, OH.
Abstract Number: LBA5009.
Date, Time and Location: June 1, 2026, 3:12 p.m. – 3:24 p.m. CDT, Arie Crown Theater
Session Type and Title: Clinical Science Symposium – Radiation Re-Imagined: Radioligand Innovation in Prostate Cancer
Late-breaking abstracts will be made publicly available at 7:00 a.m. CDT (8:00 a.m. EDT) on the day of presentation. Additional information can be found at www.asco.org
About ProstAct Global
ProstACT Global (ClinicalTrials.gov ID: NCT06520345) is an international, multi-center trial in two parts: Part 1, safety and dosimetry lead-in with 36 patients (complete); and Part 2, 2:1 randomized global expansion with an overall target enrollment of approximately 490 patients. Eligible patients must have confirmed progressive mCRPC assessed with a 68Ga-PSMA-11 PET1 imaging agent (such as Illuccix®, kit for the preparation of gallium-68 (68Ga) gozetotide injection, or Gozellix®, kit for the preparation of gallium-68 (68Ga) gozetotide injection) following prior treatment with one androgen receptor pathway inhibitor (ARPI).
The antibody approach demonstrates different targeting and pharmacology to that observed in other PSMA-targeted small molecule radioligand therapies (RLT). In contrast to these therapies2, collective long-term follow-up of patients administered with TLX591-Tx has not observed significant acute or delayed kidney toxicity, as the agent is primarily cleared through the liver, a comparatively radioresistant organ, instead of the kidneys3. Due to its large molecular weight, TLX591-Tx also demonstrates minimal salivary and lacrimal gland uptake, reducing dry mouth and dry eyes, common adverse effects of existing PSMA-targeted RLTs4.
Additional information on the Phase 3 ProstACT Global study can be found at: https://telixpharma.com/prostact/
TLX591-Tx has not received a marketing authorization in any jurisdiction.
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
| Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com | Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com | Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com |
| Media Contact Eliza Schleifstein 917.763.8106 (Mobile) Eliza@schleifsteinpr.com | ||
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
_______________________________
1 Positron emission tomography.
2 Tagawa et al. Curr Oncol Rep. 2021; Steinhelfer et al. J Nucl Med. 2024.
3 Tagawa et al. Cancer. 2019.
4 Pepin et al. Pract Radiat Oncol. 2025.
